2026 Science of Skin Summit

September 17, 2026 to September 20, 2026

Research surrounding skincare and aesthetic medicine is evolving quickly, leading to continual advancements in products and treatment approaches. In addition, dermatologic conditions such as hidradenitis suppurativa, alopecia areata, chronic spontaneous urticaria, pruritus, atopic dermatitis, acne, vitiligo, skin cancer, non-melanoma skin cancer (NMSC), melanoma, and rosacea can significantly impact patients’ quality of life, affecting their physical, emotional, social, and economic well-being. To provide optimal patient care, the dermatology community continues to pursue innovative therapies and evidence-based strategies aimed at improving outcomes and quality of life for individuals living with these conditions. Therefore, ongoing educational opportunities are critical to keeping dermatologists and other healthcare professionals informed of the latest clinical developments and treatment advances.

The skincare industry continues to grow rapidly, with consumers increasingly turning to over-the-counter (OTC) products to improve both the appearance and health of their skin. As a result, it is essential for medical practitioners to remain informed about the scientific evidence, efficacy, and safety of these products in order to effectively educate and guide their patients.

The Science of Skin Summit is designed to provide comprehensive education on practice management, skincare ingredients, AI in dermatology, longevity, hair nutraceuticals and supplements, and topical therapeutics for common skin conditions. The program will also explore the science behind a wide range of dermatologic procedures and treatment options. In addition, attendees will receive updates on the diagnosis and management of conditions including alopecia areata, hidradenitis suppurativa, chronic spontaneous urticaria, pruritus, atopic dermatitis, acne, psoriasis, skin cancer, NMSC, melanoma, actinic keratosis, and rosacea. Educational content will be delivered through a variety of proven learning formats, including expert panel discussions and didactic lectures.

 

 

Target Audience

This activity is designed for an audience of nurses, physicians, and physician associate.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Review current treatment options for patients with alopecia areata and scarring alopecia.
  • Review the evolving landscape of non-steroidal therapies in dermatology, including topical agents, targeted oral therapies, and biologics, and discuss their role in the treatment of inflammatory, autoimmune, and chronic skin conditions.
  • Compare new and emerging therapies for Atopic Dermatitis (AD)
  • Review current evidence and updated guidelines to select and individualize safe and effective acne vulgaris treatment strategies, including new and emerging therapies.
  • Describe the current and emerging applications of artificial intelligence and machine learning in dermatology clinical practice.
  • Review treatment strategies, based on knowledge of the indications, efficacy, and risks of available rosacea therapies, to achieve therapeutic goals in rosacea treatment.
  • Describe advances in the management of patients with Chronic spontaneous urticaria.
  • Review the prevalence, severity, and impact of hidradenitis suppurativa (HS).
  • Discuss advances in treatment of melanoma and non-melanoma skin carcinomas.
  • Review new and emerging treatments for non-melanoma and melanoma skin cancers.
  • Describe the biologic processes associated with aging and longevity in dermatology.
  • Review current and emerging approaches related to longevity and regenerative dermatology.
  • Discuss the current and emerging therapies available to manage moderate to severe psoriasis.
  • Review the latest advanced techniques in lasers, light, ultrasound, and radiofrequency devices.
  • Review treatment options for patients with hair loss.
  • Describe advances in the management of patients with vitiligo.
  • Describe the applications of neurotoxins, dermal fillers, surgical techniques, and minimally invasive procedures in facial rejuvenation and the treatment of submental fat.
  • Discuss indications, contraindications, and properties of existing and emerging neuromodulators and dermal fillers approved for use in the US.
  • Recognize the aesthetic implications of GLP-1–induced weight loss therapies and review evidence-based strategies for addressing facial volume loss and skin laxity through non-surgical interventions such as dermal fillers and energy-based skin tightening.
  • Develop strategies to build and maintain a professional presence that supports career growth, visibility, and credibility in the field of dermatology.
  • Review effective patient communication strategies that improve understanding, trust, and overall patient experience.
  • Describe how to build a product regimen to achieve the goals for a particular patient.
  • Identify evidence-based approaches for selecting and incorporating topical ingredients into individualized treatment plans for various skin conditions and aesthetic concerns.
Course summary
Available credit: 
  • 21.00 AAPA Category 1 CME

    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 21.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • 21.00 AMA PRA Category 1 Credit™

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 21.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 21.00 ANCC Contact Hours

    Credit being awarded: 21.00 ANCC contact hours

  • 21.00 AMA PRA Category 1 Credit™ Non-MD

    Non-Physicians Seeking AMA Credit
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 21.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

Course opens: 
09/17/2026
Course expires: 
12/31/2026
Event starts: 
09/17/2026 - 1:00pm EDT
Event ends: 
09/20/2026 - 12:00pm EDT
Cost:
$0.00
Add to calendar: 
Rating: 
0

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.

Austin, TX
United States

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

 

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Committee Member, Planner, Staff(s)

Edward Lain, MD

has a financial relationship (Advisor) with Galderma;.
has a financial relationship (Consultant) with Galderma;.
Speaker, Instructor, Faculty(s)

Vivian Bucay, MD, FAAD

has a financial relationship (Advisor) with Senté ;.
has a financial relationship (Advisor) with PCA Skin/CP Skin Health;.
has a financial relationship (Speaker) with Avène/Pierre Fabre;.
has a financial relationship (Advisor) with AO2 Skin;.
has a financial relationship (Speaker) with Skinceuticals/L'Oréal;.
has a financial relationship (Advisor) with SkinBetter Science/L'Oréal;.
has a financial relationship (Consultant) with SkinMedica/AbbVie;.
has a financial relationship (Advisor) with Estee Lauder;.
has a financial relationship (Speaker) with Eucerin/Beiersdorf;.

Lesley Clark-Loeser, MD, FAAD

has a financial relationship (Speaker) with Alastin/Galderma;.
has a financial relationship (Researcher) with Acclaro;.
has a financial relationship (Advisor) with AnteAge;.
has a financial relationship (Speaker) with Candela;.
has a financial relationship (Speaker) with BTL;.
has a financial relationship (Speaker) with Evolus;.
has a financial relationship (Advisor) with Neova;.
has a financial relationship (Speaker) with Prollenium;.
has a financial relationship (Advisor) with Revance;.
has a financial relationship (Speaker) with Scientis;.
has a financial relationship (Advisor) with SkinBetter;.

Michael Gold, M.D.

has a financial relationship (Consultant) with Acclaro;.
has a financial relationship (Consultant) with Advalight;.
has a financial relationship (Consultant) with Aerolase;.
has a financial relationship (Consultant) with Aesthetic Management Partners;.
has a financial relationship (Consultant) with Alastin/Galderma;.
has a financial relationship (Consultant) with Allergan Aesthetics/AbbVie;.
has a financial relationship (Consultant) with Alma Lasers;.
has a financial relationship (Consultant) with Bausch Health/Solta;.
has a financial relationship (Researcher) with Bausch Health/Solta;.
has a financial relationship (Consultant) with Benev;.
has a financial relationship (Consultant) with Croma;.
has a financial relationship (Researcher) with Benev;.
has a financial relationship (Researcher) with Croma;.
has a financial relationship (Consultant) with Cutera;.
has a financial relationship (Consultant) with EndyMed;.
has a financial relationship (Consultant) with ExocoBio;.
has a financial relationship (Consultant) with Hugel;.
has a financial relationship (Researcher) with Hugel;.
has a financial relationship (Consultant) with IBSA;.
has a financial relationship (Researcher) with IBSA;.
has a financial relationship (Consultant) with InMode;.
has a financial relationship (Consultant) with La Mer;.
has a financial relationship (Consultant) with Leo Pharma;.
has a financial relationship (Consultant) with Lumenis;.
has a financial relationship (Researcher) with Leo Pharma;.
has a financial relationship (Researcher) with Lumenis;.
has a financial relationship (Consultant) with Merz;.
has a financial relationship (Researcher) with Merz;.
has a financial relationship (Consultant) with MTF;.
has a financial relationship (Researcher) with MTF;.
has a financial relationship (Researcher) with Nordberg Medical;.
has a financial relationship (Consultant) with Nutrafol;.
has a financial relationship (Consultant) with Pierre Fabre/Glytone;.
has a financial relationship (Consultant) with Prescriber's Choice;.
has a financial relationship (Consultant) with Revance/Crown;.
has a financial relationship (Researcher) with Revance/Crown;.
has a financial relationship (Consultant) with Revision Skin Care;.
has a financial relationship (Researcher) with Revision Skin Care;.
has a financial relationship (Consultant) with Sciton;.
has a financial relationship (Consultant) with Sensus Healthcare;.
has a financial relationship (Consultant) with Skinbetter Science;.
has a financial relationship (Researcher) with Skinbetter Science;.
has a financial relationship (Consultant) with SkinCeuticals;.
has a financial relationship (Consultant) with Skin Medica;.
has a financial relationship (Consultant) with Sofwave;.
has a financial relationship (Researcher) with Sofwave;.
has a financial relationship (Consultant) with Stratpharma;.
has a financial relationship (Researcher) with Stratpharma;.
has a financial relationship (Consultant) with Strata Skin Sciences;.
has a financial relationship (Consultant) with Venus Concept;.
has a financial relationship (Researcher) with Venus Concept;.
has a financial relationship (Consultant) with VIOL;.
has a financial relationship (Consultant) with Vydence;.

Edward Lain, MD

has a financial relationship (Advisor) with Galderma;.
has a financial relationship (Consultant) with Galderma;.

Raja Sivamani, MD

has a financial relationship (Consultant) with Arbonne;.
has a financial relationship (Consultant) with Codex Labs;.
has a financial relationship (Consultant) with Burts Bees;.
has a financial relationship (Consultant) with Bristol Meyers Squibb;.
has a financial relationship (Consultant) with Blueprints Medicine;.
has a financial relationship (Consultant) with Incyte;.
has a financial relationship (Consultant) with Nutraceutical Wellness;.
has a financial relationship (Consultant) with Galderma;.
has a financial relationship (Consultant) with Amgen;.
has a financial relationship (Consultant) with Almiral;.
has a financial relationship (Consultant) with Trace Mineral ;.
has a financial relationship (Consultant) with Abbvie;.
has a financial relationship (Consultant) with Leo;.
has a financial relationship (Consultant) with UCB;.
has a financial relationship (Speaker) with Sun Pharmaceuticals ;.
has a financial relationship (Consultant) with Pfizer ;.
has a financial relationship (Consultant) with Phothera;.
has a financial relationship (Consultant) with Regeneron Pharmaceuticals;.
has a financial relationship (Consultant) with Janssen;.
has a financial relationship (Consultant) with Arcutis;.
has a financial relationship (Consultant) with Novartis;.
has a financial relationship (Consultant) with Lily;.
has a financial relationship (Speaker) with Bristol Myers Squibb;.
has a financial relationship (Speaker) with Incyte;.
has a financial relationship (Speaker) with Galderma;.
has a financial relationship (Speaker) with Almirall;.
has a financial relationship (Speaker) with Abbvie;.
has a financial relationship (Speaker) with Leo;.
has a financial relationship (Speaker) with UCB;.
has a financial relationship (Speaker) with Pfizer;.
has a financial relationship (Speaker) with Phothera;.
has a financial relationship (Speaker) with Regeneron Pharmaceuticals;.
has a financial relationship (Speaker) with Janssen;.
has a financial relationship (Speaker) with Lilly;.

Linda Stein Gold, MD

has a financial relationship (Advisor) with Abbvie;.
has a financial relationship (Advisor) with Amgen;.
has a financial relationship (Advisor) with Arcutis;.
has a financial relationship (Advisor) with J&J;.
has a financial relationship (Advisor) with Takeda;.
has a financial relationship (Advisor) with Lilly;.
has a financial relationship (Advisor) with Organon;.
has a financial relationship (Advisor) with Alumis;.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Science of Skin Summit. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

This activity was planned by and for the healthcare team, and learners will receive 21 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Available Credit

  • 21.00 AAPA Category 1 CME

    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 21.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • 21.00 AMA PRA Category 1 Credit™

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 21.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 21.00 ANCC Contact Hours

    Credit being awarded: 21.00 ANCC contact hours

  • 21.00 AMA PRA Category 1 Credit™ Non-MD

    Non-Physicians Seeking AMA Credit
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 21.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

Price

Cost:
$0.00
Please login or register to take this course.